BDX:NYE-Becton Dickinson and Company (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 229.54

Change

0.00 (0.00)%

Market Cap

USD 65.91B

Volume

1.81M

Analyst Target

USD 276.71
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-09 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ALC Alcon AG

N/A

USD 46.01B
RMD ResMed Inc

N/A

USD 34.14B
BAX Baxter International Inc

N/A

USD 18.71B
AVTR Avantor Inc

N/A

USD 11.92B
ATR AptarGroup Inc

N/A

USD 10.16B
TFX Teleflex Incorporated

N/A

USD 7.78B
STVN Stevanato Group SpA

N/A

USD 5.98B
BLCO Bausch + Lomb Corp

N/A

USD 5.64B
WRBY Warby Parker Inc

N/A

USD 3.17B
INFU InfuSystems Holdings Inc

N/A

USD 0.17B

ETFs Containing BDX

UMDV:SW iShares US Medical Device.. 6.00 % 0.00 %

N/A

N/A
FHI:CA CI Health Care Giants Cov.. 5.20 % 0.75 %

N/A

CAD 0.10B
EQTY Kovitz Core Equity ETF 4.18 % 0.00 %

N/A

USD 1.25B
SPQB:XETRA Global X S&P 500® Quarte.. 3.93 % 0.00 %

N/A

N/A
LS:CA 3.23 % 2.21 %

N/A

N/A
YLDE ClearBridge Dividend Stra.. 3.07 % 0.59 %

N/A

USD 0.05B
TEQI T. Rowe Price Equity Inco.. 1.83 % 0.00 %

N/A

USD 0.30B
IBDK 0.00 % 0.10 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
VSL 0.00 % 0.65 %

N/A

N/A
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.00 %

N/A

CAD 0.05B
EWRD:XETRA 0.00 % 0.00 %

N/A

N/A
NSGE:CA NBI Sustainable Global Eq.. 0.00 % 0.00 %

N/A

CAD 0.53B
TULV:CA TD Q U.S. Low Volatility .. 0.00 % 0.00 %

N/A

CAD 0.07B
TACE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.18% 68% D+ 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.18% 68% D+ 57% F
Trailing 12 Months  
Capital Gain -4.32% 63% D 28% F
Dividend Return 1.23% 70% C- 22% F
Total Return -3.09% 58% F 25% F
Trailing 5 Years  
Capital Gain -0.86% 56% F 37% F
Dividend Return 7.21% 86% B+ 17% F
Total Return 6.36% 56% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -0.91% 37% F 27% F
Dividend Return 0.46% 42% F 23% F
Total Return 1.37% 70% C- 32% F
Risk Return Profile  
Volatility (Standard Deviation) 7.26% 100% F 85% B
Risk Adjusted Return 6.34% 42% F 24% F
Market Capitalization 65.91B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector